Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept

Core Insights - Vera Therapeutics, Inc. has received FDA priority review for Atacicept, aimed at treating immunoglobulin A nephropathy (IgAN) [1][2] - The drug's approval could allow for at-home administration via weekly injections, enhancing patient care [2] - Recent trial results show Atacicept's efficacy, with a 46% decline in proteinuria and a 42% reduction in urine protein-to-creatinine ratio compared to placebo [3] Stock Performance - Vera Therapeutics' shares have increased nearly 53% over the past three months [4] - Wall Street's average one-year price target for the stock is $74.08, indicating a potential upside of 59.45% [4] - Analysts from Guggenheim and LifeSci Capital have reiterated their Buy ratings, with price targets of $56 and $70 respectively [4] Company Overview - Vera Therapeutics is a clinical-stage biotech company focused on developing treatments for complex immunological diseases [5]